Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Bladder Cancer

Free Subscription 02.07.2018 1 Adv Sci (Weinh) 1 Asia Pac J Clin Oncol 1 Cancer Discov 1 Cancer Med 1 Cell Oncol (Dordr) 1 Cell Physiol Biochem 1 Clin Cancer Res 1 Curr Oncol Rep 1 Curr Urol Rep 1 Diabetes Res Clin Pract 1 Drug Des Devel Ther 1 EBioMedicine 1 Eur J Pharm Biopharm 1 Eur J Surg Oncol 1 Eur Urol 1 Int J Radiat Oncol Biol Phys 1 J Agric Food Chem 1 J Cancer Res Clin Oncol 1 J Clin Lab Anal 1 J Int Med Res 1 JAMA Surg 1 Neoplasma 1 Onco Targets Ther 1 Oncogene 1 PLoS One 2 Rev Urol 1 Turk J Urol 5 World J Urol

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Adv Sci (Weinh)

1. GUO H, Li F, Xu W, Chen J, et al
   Mucoadhesive Cationic Polypeptide Nanogel with Enhanced Penetration for Efficient Intravesical Chemotherapy of Bladder Cancer.
   Adv Sci (Weinh). 2018;5:1800004.
   PubMed     Text format     Abstract available
   
   

   
   Asia Pac J Clin Oncol

2. MI Y, Zhao Y, Shi F, Zhang M, et al
   Diagnostic accuracy of urine cytokeratin 20 for bladder cancer: A meta-analysis.
   Asia Pac J Clin Oncol. 2018 Jun 22. doi: 10.1111/ajco.13024.
   PubMed     Text format     Abstract available
   
   

   
   Cancer Discov

3. 
   Erdafitinib Efficacious in Bladder Cancer.
   Cancer Discov. 2018 Jun 27. pii: 2159-8290.CD-NB2018.
   PubMed     Text format     Abstract available
   
   

   
   Cancer Med

4. LIN N, Wu YP, Lin YZ, Tao X, et al
   Risk factors for upper tract urothelial recurrence following local excision of bladder cancer.
   Cancer Med. 2018 Jun 28. doi: 10.1002/cam4.1642.
   PubMed     Text format     Abstract available
   
   

   
   Cell Oncol (Dordr)

5. DUDEK AM, Vermeulen SH, Kolev D, Grotenhuis AJ, et al
   Identification of an enhancer region within the TP63/LEPREL1 locus containing genetic variants associated with bladder cancer risk.
   Cell Oncol (Dordr). 2018 Jun 28. pii: 10.1007/s13402-018-0393.
   PubMed     Text format     Abstract available
   
   

   
   Cell Physiol Biochem

6. WANG J, Fang R, Wang L, Chen G, et al
   Identification of Carbonic Anhydrase IX as a Novel Target for Endoscopic Molecular Imaging of Human Bladder Cancer.
   Cell Physiol Biochem. 2018;47:1565-1577.
   PubMed     Text format     Abstract available
   
   

   
   Clin Cancer Res

7. LELO A, Prip F, Harris BT, Solomon D, et al
   STAG2 Is a Biomarker for Prediction of Recurrence and Progression in Papillary Non-Muscle-Invasive Bladder Cancer.
   Clin Cancer Res. 2018 Jun 28. pii: 1078-0432.CCR-17-3244.
   PubMed     Text format     Abstract available
   
   

   
   Curr Oncol Rep

8. JOHNSON SB, Yu JB
   Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer.
   Curr Oncol Rep. 2018;20:66.
   PubMed     Text format     Abstract available
   
   

   
   Curr Urol Rep

9. SALTZMAN AF, Cost NG
   Current Treatment of Pediatric Bladder and Prostate Rhabdomyosarcoma.
   Curr Urol Rep. 2018;19:11.
   PubMed     Text format     Abstract available
   
   

   
   Diabetes Res Clin Pract

10. DAVIDSON MB, Pan D
    Erratum to "An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug's effect on cardiovascular disease and non-alcoholic steatohepatitis" [Diab. Res. Clin. Pract. 135 (2018) 102-110].
    Diabetes Res Clin Pract. 2018 Jun 20. pii: S0168-8227(18)30968.
    PubMed     Text format    
    
    

    
    Drug Des Devel Ther

11. BOURN J, Cekanova M
    Cyclooxygenase inhibitors potentiate receptor tyrosine kinase therapies in bladder cancer cells in vitro.
    Drug Des Devel Ther. 2018;12:1727-1742.
    PubMed     Text format     Abstract available
    
    

    
    EBioMedicine

12. YANG Z, Zhang R, Ge Y, Qin X, et al
    Somatic FGFR3 Mutations Distinguish a Subgroup of Muscle-Invasive Bladder Cancers with Response to Neoadjuvant Chemotherapy.
    EBioMedicine. 2018 Jun 22. pii: S2352-3964(18)30218.
    PubMed     Text format     Abstract available
    
    

    
    Eur J Pharm Biopharm

13. APFELTHALER C, Skoll K, Ciola R, Gabor F, et al
    A Doxorubicin loaded colloidal delivery system for the intravesical therapy of non-muscle invasive bladder cancer using wheat germ agglutinin as targeter.
    Eur J Pharm Biopharm. 2018 Jun 27. pii: S0939-6411(18)30082.
    PubMed     Text format     Abstract available
    
    

    
    Eur J Surg Oncol

14. VOSKUILEN CS, Fransen van de Putte EE, Perez-Reggeti JI, van Werkhoven E, et al
    Prostate sparing cystectomy for bladder cancer: A two-center study.
    Eur J Surg Oncol. 2018 Jun 8. pii: S0748-7983(18)31115.
    PubMed     Text format     Abstract available
    
    

    
    Eur Urol

15. THOENY HC, Bellin MF, Comperat EM, Thalmann GN, et al
    Vesical Imaging-Reporting and Data System (VI-RADS): Added Value for Management of Bladder Cancer Patients?
    Eur Urol. 2018 Jun 27. pii: S0302-2838(18)30442.
    PubMed     Text format    
    
    

    
    Int J Radiat Oncol Biol Phys

16. TANAKA H, Yoshida S, Koga F, Toda K, et al
    Impact of Immunohistochemistry-Based Subtypes in Muscle-Invasive Bladder Cancer on Response to Chemoradiotherapy.
    Int J Radiat Oncol Biol Phys. 2018 Jun 27. pii: S0360-3016(18)31021.
    PubMed     Text format     Abstract available
    
    

    
    J Agric Food Chem

17. XIA Y, Yuan M, Li S, Thuan UT, et al
    Apigenin suppresses IL-1beta-induced expression of urokinase-type plasminogen activator receptor by inhibiting MAPK-mediated AP-1 and NF-small ka, CyrillicB signaling in human bladder cancer T24 cells.
    J Agric Food Chem. 2018 Jun 27. doi: 10.1021/acs.jafc.8b02351.
    PubMed     Text format     Abstract available
    
    

    
    J Cancer Res Clin Oncol

18. RINALDETTI S, Wirtz R, Worst TS, Hartmann A, et al
    FOXM1 predicts disease progression in non-muscle invasive bladder cancer.
    J Cancer Res Clin Oncol. 2018 Jun 29. pii: 10.1007/s00432-018-2694.
    PubMed     Text format     Abstract available
    
    

    
    J Clin Lab Anal

19. BEN WAFI S, Kallel A, Ben Fradj MK, Sallemi A, et al
    Haplotype-based association of Vascular Endothelial Growth Factor gene polymorphisms with urothelial bladder cancer risk in Tunisian population.
    J Clin Lab Anal. 2018 Jun 29:e22610. doi: 10.1002/jcla.22610.
    PubMed     Text format     Abstract available
    
    

    
    J Int Med Res

20. ZHOU X, Ji H, Zhang H, Xiong T, et al
    Treatment and outcomes of urethral recurrence after orthotopic neobladder replacement in patients with bladder cancer - practice in a single centre.
    J Int Med Res. 2018 Jan 1:300060518782015. doi: 10.1177/0300060518782015.
    PubMed     Text format     Abstract available
    
    

    
    JAMA Surg

21. WILLIAMS SB, Shan Y, Jazzar U, Mehta HB, et al
    Comparing Survival Outcomes and Costs Associated With Radical Cystectomy and Trimodal Therapy for Older Adults With Muscle-Invasive Bladder Cancer.
    JAMA Surg. 2018 Jun 27. pii: 2685879. doi: 10.1001/jamasurg.2018.1680.
    PubMed     Text format     Abstract available
    
    

    
    Neoplasma

22. FENG SQ, Zhang XY, Fan HT, Sun QJ, et al
    Up-regulation of LncRNA MEG3 inhibits cell migration and invasion and enhances cisplatin chemosensitivity of bladder cancer cells.
    Neoplasma. 2018 Jun 26. doi: 10.4149/neo_2018_180125.
    PubMed     Text format     Abstract available
    
    

    
    Onco Targets Ther

23. LI J, Cheng Y, Liu G, Ji Z, et al
    The association of pretreatment serum albumin with outcomes in bladder cancer: a meta-analysis.
    Onco Targets Ther. 2018;11:3449-3459.
    PubMed     Text format     Abstract available
    
    

    
    Oncogene

24. PENG M, Wang J, Zhang D, Jin H, et al
    PHLPP2 stabilization by p27 mediates its inhibition of bladder cancer invasion by promoting autophagic degradation of MMP2 protein.
    Oncogene. 2018 Jun 21. pii: 10.1038/s41388-018-0374.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

25. BECKFORD VERA DR, Smith CC, Bixby LM, Glatt DM, et al
    Immuno-PET imaging of tumor-infiltrating lymphocytes using zirconium-89 radiolabeled anti-CD3 antibody in immune-competent mice bearing syngeneic tumors.
    PLoS One. 2018;13:e0193832.
    PubMed     Text format     Abstract available
    
    

    
    Rev Urol

26. BJURLIN MA
    Management of Recurrent Non-Muscle Invasive Bladder Cancer.
    Rev Urol. 2018;20:38-40.
    PubMed     Text format    
    
    
27. VELAZQUEZ N
    Bladder Cancer Academy 2018 Selected Summaries.
    Rev Urol. 2018;20:31-37.
    PubMed     Text format    
    
    

    
    Turk J Urol

28. ISLAMOGLU E, Anil H, Erol I, Tas S, et al
    Robotic radical cystectomy for the management of bladder cancer: Analysis of operative and pathological outcomes of eighteen patient.
    Turk J Urol. 2018;44:311-315.
    PubMed     Text format     Abstract available
    
    

    
    World J Urol

29. SORIA F, Droller MJ, Lotan Y, Gontero P, et al
    An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer.
    World J Urol. 2018 Jun 21. pii: 10.1007/s00345-018-2380.
    PubMed     Text format     Abstract available
    
    
30. GARCIA-PERDOMO HA, Montes-Cardona CE, Guacheta M, Castillo DF, et al
    Muscle-invasive bladder cancer organ-preserving therapy: systematic review and meta-analysis.
    World J Urol. 2018 Jun 25. pii: 10.1007/s00345-018-2384.
    PubMed     Text format     Abstract available
    
    
31. KRABBE LM, Margulis V, Schrader AJ, Shariat SF, et al
    Molecularly-driven precision medicine for advanced bladder cancer.
    World J Urol. 2018 Jun 8. pii: 10.1007/s00345-018-2354.
    PubMed     Text format     Abstract available
    
    
32. RINGUETTE-GOULET C, Bolduc S, Pouliot F
    Modeling human bladder cancer.
    World J Urol. 2018 Jun 14. pii: 10.1007/s00345-018-2369.
    PubMed     Text format     Abstract available
    
    
33. FLETCHER SA, Harmouch SS, Krimphove MJ, Cole AP, et al
    Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era.
    World J Urol. 2018 Jun 14. pii: 10.1007/s00345-018-2371.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: